title: The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?
authors.affiliation: Di.Bi.M.I.S., Division of Internal Medicine, 'Villa Sofia-Cervello' Hospital, University of Palermo, Italy fsmacaluso@gmail.com.
authors.forename: Fabio Salvatore
authors.initials: FS
authors.lastname: Macaluso
authors.affiliation: Di.Bi.M.I.S., Division of Internal Medicine, 'Villa Sofia-Cervello' Hospital, University of Palermo, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Cottone
authors.affiliation: Di.Bi.M.I.S., Division of Internal Medicine, 'Villa Sofia-Cervello' Hospital, University of Palermo, Italy.
authors.forename: Ambrogio
authors.initials: A
authors.lastname: Orlando
mesh_terms: D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D007155:Immunologic Factors; D000069285:Infliximab
keywords: Anti-TNF; Crohn’s disease; combination therapy; immunomodulator